DTDaniel Teran

Daniel Teran

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daniel Teran has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Hamza Almusabeh

    Department of Medicine, West Virginia University School of Medicine, Morgantown, WV

    1 shared publication
  • Jennifer Hadam-Veverka

    Section of Gastroenterology and Hepatology, Department of Medicine, West Virginia University School of Medicine

    1 shared publication
  • Kanwarpreet Tandon

    Section of Gastroenterology and Hepatology, Department of Medicine, West Virginia University School of Medicine

    1 shared publication
  • Katherine Shepherd

    Department of Medicine, West Virginia University School of Medicine

    1 shared publication
  • Khaled Elfert

    Section of Gastroenterology and Hepatology, Department of Medicine, West Virginia University School of Medicine

    1 shared publication
  • Megan Vaughan

    Department of Medicine, West Virginia University School of Medicine

    1 shared publication

Latest Publications

  • Comparing the risk of heart failure in patients with inflammatory bowel disease treated with infliximab versus adalimumab: a retrospective cohort study using a national database

    by Hamza Almusabeh, Mohamad Alzaher, Megan Vaughan, Daniel Teran, Zachary Kovac, Olanrewaju Adeniran, Katherine Shepherd, Khaled Elfert, Sanya Goswami, Jennifer Hadam-Veverka, et al.

    Anti–tumor necrosis factor (TNF) agents are widely used for inflammatory bowel disease and have well-documented heart failure risk, but comparative cardiac safety remains uncertain. We conducted a retrospective cohort study using the TriNetX US national database. Adults with Crohn’s disease or ulcerative colitis initiating infliximab or adalimumab were included. Patients with prior heart failure were excluded. The primary outcome was heart failure occurring ≥ 6 months after anti-TNF initiation. Propensity score matching was performed to balance baseline covariates. Before matching, 25,582 patients received infliximab and 24,301 received adalimumab. After matching, 21,554 remained in each group. Median follow-up was ≈ 3.65 years (infliximab) and ≈ 3.91 years (adalimumab). Heart failure occurred in 466 (2.21%) infliximab patients vs 383 (1.81%) adalimumab patients (risk ratio, 1.22; 95% confidence interval [CI] 1.068–1.395; P = 0.003). In an exploratory Cox model, infliximab was associated with a higher heart failure hazard, 1.179 (95% CI 1.029–1.35), and a significant Kaplan-Meier curve by log-rank test (P = 0.02). In this national database analysis of patients with inflammatory bowel disease, infliximab was associated with a higher observed risk of incident heart failure compared with adalimumab.